Today hCMV is the major cause for seriously handicapped newborns and a major cause for serious adverse events during transplantation surgeries. Annual cost to healthcare systems in the US alone amount to above 4 billion USD. Currently there is still no vaccine available. The worldwide market potential is comparable to that of HPV vaccines. CAP-CMV´s candidate has been shown to trigger efficient T cell and B cell responses in animal models.